Potential Opportunity in "Epilepsy" Industry

 

Overview:

The onset of seizures in people with epilepsy is very unpredictable. The condition usually strikes people with two or more seizures, and it is impossible to predict what triggers each one. Seizures are usually caused by a specific area of the brain, and can affect the person's movement and sensory functions. The best way to identify whether or not a medication is working is to keep a seizure diary. This helps the physician determine what triggers seizures.

To Get Complete Industry Insights, Grab Sample PDF Copy Here: https://bit.ly/3K3YZm7

Market Drivers:

Growing cases of road accidents and increasing geriatric populations around the globe is expected to propel growth of the global epilepsy market over the forecast period. According to the World Health Organization (WHO), road traffic injuries are one of the leading causes of deaths in young adults and children aged 5-29 years worldwide, and nearly 1.3 million people die every year due to road accidents. These injuries are also the cause of epilepsy in many people, which drives the demand for epilepsy treatment around the world. 

Moreover, increasing expenditure by government for the development of novel and effective drugs to treat seizures is also expected to boost growth of the global epilepsy market over the forecast period. 

Market Restraints:

Increasing costs of medication and low awareness regarding epilepsy treatment among people are the factors likely to hinder growth of the global epilepsy market over the forecast period.

Regional Analysis:

Asia Pacific among regions is anticipated to witness substantial growth in the global epilepsy market over the forecast period. This growth is due to rise in awareness among patients about active epilepsy treatment in the region. 

Furthermore, North America is also anticipated to witness significant growth in the global epilepsy market over the forecast period. This can be attributed to supportive initiatives by government, increasing R&D activities for epilepsy treatment across the region. 

Key Players:

Major players operating in the global epilepsy market are Takeda, LivaNova, Bausch Health, Johnson & Johnson Services, Sunovion Pharmaceuticals, Eisai, Sanofi, GlaxoSmithKline PLC, Abbott Laboratories, Pfizer, GW Pharmaceuticals, UCB SA, Novartis AG, Medtronic PLC, and NeuroPace.

In March 2022, the U.S. Food and Drug Administration (FDA), granted approval to Ztalmy (ganaxolone) for treating seizures linked to cyclin-dependent kinase-like 5 deficiency disorder in kids aged 2 and older.